Spyre Therapeutics 3Q 2026: Net loss $96.1M, EPS ($0.94) — 10-Q Summary

What happened

Spyre Therapeutics reported a third-quarter 2026 net loss of $96.1 million, compared with an $11.2 million loss a year earlier, and diluted loss per share of $0.94 versus $0.15. The wider loss primarily reflected a $41.4 million year-over-year swing in other expense or income, mainly from revaluations of contingent value rights liabilities.

Confirmed

Global impact / market context

The larger reported loss reflects a substantial non-operating accounting swing tied mainly to liability revaluations, rather than a stated change in trial spending or sales. Investors therefore need to distinguish this item from operating costs while weighing the company’s clinical progress and continued development plans.

Analyst inference

The article describes mixed clinical evidence: one Phase 2 program showed statistically significant improvement across three monotherapies, while SPY072 trials in two other diseases missed their main goals. That combination leaves future investment dependent on advancing selected programs and producing upcoming trial results.

Analyst inference

What to watch

1. Watch for the SKYLINE Part B induction data expected in Q3 2027; the article says enrollment is ahead of schedule and the target has increased. Confirmed
2. Track the SKYLIGHT topline results expected in late 2027 or early 2028, which will test SPY072 combined with bimekizumab in hidradenitis suppurativa. Confirmed
3. The planned 2027 pivotal studies of SPY072 alone in hidradenitis suppurativa could require further trial spending; results may shape whether that program advances. Analyst inference

Evidence

• Original source link unavailable